Production (Stage)
ANI Pharmaceuticals, Inc.
ANIP
$57.79
$0.520.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.26% | 26.20% | 23.60% | 34.27% | 44.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.26% | 26.20% | 23.60% | 34.27% | 44.26% |
| Cost of Revenue | 42.04% | 37.85% | 35.84% | 39.65% | 36.64% |
| Gross Profit | 23.26% | 19.28% | 16.54% | 31.09% | 49.21% |
| SG&A Expenses | 52.87% | 46.72% | 50.46% | 42.46% | 41.67% |
| Depreciation & Amortization | 27.03% | 13.28% | 2.11% | 3.00% | 4.66% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.87% | 37.15% | 35.39% | 35.40% | 35.29% |
| Operating Income | -72.31% | -70.49% | -60.53% | 23.75% | 248.47% |
| Income Before Tax | -164.03% | -211.78% | -156.85% | 437.00% | 224.39% |
| Income Tax Expenses | -186.88% | -437.60% | -123.91% | 257.91% | 190.56% |
| Earnings from Continuing Operations | -159.21% | -198.63% | -152.99% | 623.65% | 235.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -159.21% | -198.63% | -152.99% | 623.65% | 235.02% |
| EBIT | -72.31% | -70.49% | -60.53% | 23.75% | 248.47% |
| EBITDA | -19.47% | -24.67% | -28.83% | 8.77% | 50.05% |
| EPS Basic | -171.36% | -220.85% | -183.30% | 365.54% | 194.52% |
| Normalized Basic EPS | -126.27% | -128.27% | -93.67% | 107.59% | 323.99% |
| EPS Diluted | -173.56% | -224.65% | -189.91% | 353.94% | 192.64% |
| Normalized Diluted EPS | -127.34% | -129.31% | -94.29% | 106.82% | 320.32% |
| Average Basic Shares Outstanding | 4.16% | 7.37% | 10.88% | 14.39% | 14.37% |
| Average Diluted Shares Outstanding | 3.43% | 6.68% | 10.78% | 15.03% | 15.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -2.69% | -2.01% | -2.89% | 1.19% | 1.74% |